Pompe Disease Therapeutics Market to Grow with a CAGR of 4.45% through 2028
Increased
Disease Awareness and Diagnosis and increase in the global disease burden is
expected to drive the Global Pompe Disease Therapeutics Market growth in the forecast
period, 2024-2028.
According to
TechSci Research report, “Pompe Disease Therapeutics Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities,
2028”, the Global Pompe Disease Therapeutics Market stood at USD 1.40
billion in 2022 and is anticipated to grow with a CAGR of 4.45% in the forecast
period, 2024-2028. The awareness among individuals regarding Pompe Disease
Therapeutics has led to favorable market conditions for the global Pompe
Disease Therapeutics market. Several factors contribute to the growth of
various Pompe Disease Therapeutics products.
A major factor
driving the Pompe Disease Therapeutics Market is the continuous progression in
therapeutic strategies. While Enzyme Replacement Therapy (ERT), involving the administration
of a synthetic enzyme, remains the fundamental treatment, ongoing research has
yielded pioneering therapeutic approaches like gene therapy, small molecule
treatments, and precision medicine. These advancements broaden the spectrum of
available treatments, holding the potential to enhance patient outcomes and
overall quality of life.
Pharmaceutical
firms, academic establishments, and research institutions are progressively
channeling investments into research and development endeavors centered on
Pompe disease. This elevated dedication to scientific inquiry has resulted in
significant advancements in comprehending the disease's fundamental mechanisms
and the creation of innovative therapeutic interventions. Collaborative
research initiatives and partnerships are playing a pivotal role in fostering
innovation and broadening the array of accessible treatments, which will
further fuel market growth.
In September
2020 - Genzyme Corp announces the launch of its new Pompe disease drug,
Lumizyme (alglucosidase alfa). Lumizyme is the first Pompe disease drug to be
administered subcutaneously (under the skin), which is a more convenient and
less invasive route of administration than intravenous (IV) infusion.
The worldwide
incidence of Pompe disease is increasing, driven by factors like population
growth and longer lifespans. This growing disease burden is a significant
driver behind the expansion of the Pompe Disease Therapeutics Market. With a
rising number of individuals being diagnosed with Pompe disease, there is a
continuous surge in the demand for effective treatments.
In today's
fast-paced world, Pompe disease therapeutics, including Enzyme Replacement
Therapy (ERT), enable early diagnosis and intervention. In a fast-paced world
where time is of the essence, these treatments help prevent the progression of
the disease, allowing patients to maintain a higher quality of life. Effective
therapeutics can enhance the productivity of individuals with Pompe disease. By
managing symptoms and improving muscle function, patients can remain active in
their daily lives and contribute to the workforce, supporting a thriving
economy. Timely treatment with Pompe disease therapeutics reduces the burden on
healthcare systems. Preventing severe complications and hospitalizations
contributes to more efficient healthcare delivery, ensuring that resources are
allocated effectively. Pompe disease therapeutics not only extend life but also
enhance its quality. Patients can continue to engage in social, professional,
and recreational activities, allowing them to lead fulfilling lives in a
fast-paced society.
The growing
awareness of Pompe disease therapeutics has transformed the lives of patients
by improving their overall quality of life. Patients can now enjoy a better
quality of life, remain more active, and participate more fully in their
communities and daily activities.
In recent times,
there has been a increasing focus on early diagnosis of rare diseases like
Pompe disease. Pompe disease therapeutics play a crucial role in managing the
condition when diagnosed early, preventing the progression of debilitating
symptoms and improving patient outcomes. Ongoing research has led to
significant advancements in Pompe disease therapeutics. Enzyme Replacement
Therapy (ERT) and other innovative treatment approaches have become more
refined and effective, offering better symptom management and quality of life
improvements for patients. Recent efforts have been made to enhance patient
access to Pompe disease therapeutics. This includes regulatory support,
expanded insurance coverage, and patient assistance programs, making these
treatments more accessible to those in need. International collaboration among
researchers, healthcare professionals, and patient advocacy groups has accelerated
the development and dissemination of Pompe disease therapeutics. This
collaborative approach has facilitated knowledge sharing and treatment
availability worldwide. However, the limited supply of natural Pompe Disease
Therapeutics raw materials may hinder market growth. Moreover, challenges
related to ingredient shortages and price sensitivity may pose obstacles to the
Pompe Disease Therapeutics market in the near future.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Pompe Disease Therapeutics Market.”
The Global Pompe
Disease Therapeutics Market is segmented into Treatment type, route of
administration, distribution channel, regional distribution, and company.
Based on its
treatment type, the Enzyme Replacement Therapy (ERT) stands out as the primary
therapeutic approach for managing Pompe disease. This treatment method entails
the direct administration of a synthetic version of the deficient GAA enzyme
into the patient's bloodstream. ERT effectively takes the place of the missing
enzyme, facilitating the breakdown of accumulated glycogen within the body's
tissues. ERT has consistently demonstrated remarkable effectiveness in
enhancing both muscle function and the overall quality of life for individuals
grappling with Pompe disease. Extensive clinical trials and long-term studies
have consistently yielded positive results, including notable gains in muscle
strength and improved respiratory function. The safety profile of ERT is firmly
established. Although some patients may encounter mild infusion-related
reactions, these can be effectively managed. The overall safety record of ERT
has played a pivotal role in its widespread acceptance and adoption.
Remarkably, ERT not only alleviates the symptoms of Pompe disease but also
effectively stabilizes the progression of the condition. Patients undergoing
ERT treatment tend to experience a slower rate of decline in muscle function,
thereby reducing the risk of life-threatening respiratory complications.
Based on region,
North America segment is expected to grow during the forecast
period. North America, including The United States experiences a
comparatively higher incidence of Pompe disease than many other regions,
necessitating a larger market to cater to the treatment requirements of
affected individuals. North America possesses a robust healthcare
infrastructure, featuring well-established hospitals, specialized clinics, and
research institutions, which facilitates efficient diagnosis and treatment
delivery. Regulatory bodies in North America, including the U.S. Food and Drug
Administration (FDA), have proactively granted orphan drug designations and
fast-track approvals for Pompe disease therapies, hastening their availability.
Prominent pharmaceutical companies in North America have made substantial
investments in Pompe disease research and development, resulting in a wide
array of treatment options.
The Asia-Pacific
market is poised to be the fastest-growing market, offering lucrative growth
opportunities for Pompe Disease Therapeutics players during the forecast
period. Factors such as increasing Awareness and recognition of Pompe disease
are growing in the Asia-Pacific region, leading to more accurate diagnoses and
a larger patient pool. Many countries in the region are investing in expanding
and modernizing their healthcare infrastructure, including specialized
treatment centers. Emerging economies in Asia, such as India and China, are
witnessing rapid economic growth and urbanization. This growth is accompanied
by increased healthcare spending and access to advanced treatments.
Collaboration between regional research institutions and international partners
is driving Pompe disease research and clinical trials in the Asia-Pacific
region.
Major companies
operating in Global Pompe Disease Therapeutics Market are:
- Genzyme Corp
- Amicus Therapeutics Inc
- Valerion Therapeutics LLC
- Audentes Therapeutics Inc
- Actus Therapeutics Inc
- BioMarin Pharmaceutical Inc
- EpiVax inc
- Oxyrane Co Ltd.
- Sangamo BioSciences Inc
- Avrobio Inc
- Spark Therapeutics Inc
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The
Advancements in Therapeutic Approaches and Patient-Centric Approach are key
drivers of the Pompe Disease Therapeutics market. In recent years, the growing
economic implications of Pompe disease, including the demand for diagnostic
tests, therapies, and healthcare services, create opportunities for investment,
innovation, and market expansion. Moreover, the growing consumer emphasis on preventative
healthcare products has enhanced production and marketing efforts. To meet the
demands of the market, manufacturers are increasingly incorporating
cutting-edge technologies with high production efficiency. Rising consumer
acceptance and continuous product innovation will further ensure the growth of
the Pompe Disease Therapeutics and supplements market in the coming years.,”
said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based management consulting firm.
“Pompe Disease
Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, &
Forecast 2018-2028 Segmented By Treatment Type (Drugs, Enzyme Replacement
Therapy, Physical Therapy, Chaperone-Advanced Replacement Therapy), By Route of
Administration (Oral, Parenteral), By End User (Hospitals & Speciality
Clinics, Other), By Region, Competition”, has evaluated
the future growth potential of Global Pompe Disease Therapeutics Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Pompe Disease Therapeutics Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com